Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 9
Submit an article Journal homepage
461
Views
7
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment

Christine BekosDepartment of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria;
,
Thomas PerkmannClinical Institute of Laboratory Medicine and Clinical Chemistry, Medical University of Vienna, Vienna, Austria;
,
Maria KrauthDepartment of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria;
,
Markus RadererDepartment of Medicine I, Division of Clinical Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
,
Klaus LechnerDepartment of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Correspondence[email protected]
&
Ulrich JaegerDepartment of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria;
Pages 2033-2036 | Received 18 Jun 2015, Accepted 04 Dec 2015, Published online: 21 Jan 2016

References

  • Lechner K, Pabinger I, Obermeier HL, et al. Immune-mediated disorders causing bleeding or thrombosis in lymphoproliferative diseases. Semin Thromb Hemost. 2014;40:359–370.
  • Moreno C, Montillo M, Panayiotidis P, et al. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase 4, non-interventional, observational study from the European Research Initiative on chronic lymphocytic leukemia. Haematologica. 2015;100:511–6.
  • Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
  • Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma. 2013;54:2144–2148.
  • Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–1022.
  • Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9:435–444.
  • Greil R, Obrtlikova P, Smolej L, et al. Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial. Blood (Suppl) 2014;124:20.
  • Patel NS, Fung SM, Zanichelli A, et al. Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency. Allergy Asthma Proc. 2013;34:72–77.
  • Castelli R, Deliliers DL, Zingale LC, et al. Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica. 2007;92:716–718.
  • Bygum A, Vestergaard H. Acquired angioedema – occurrence, clinical features and associated disorders in a Danish nationwide patient cohort. Int Arch Allergy Immunol. 2013;162:149–155.
  • Bibi-Triki T, Eclache V, Frilay Y, et al. [Acquired C1 inhibitor deficiency associated with lymphoproliferative disorders: four cases]. Rev Med Interne. 2004;25:667–672.
  • Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ. 2006;175:1065–1070.
  • Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161:2417–2429.
  • Branellec A, Bouillet L, Javaud N, et al. Acquired C1-inhibitor deficiency: 7 patients treated with rituximab. J Clin Immunol. 2012;32:936–941.
  • Lam DH, Levy NB, Nickerson JM, et al. Acquired angioedema and marginal zone lymphoma. J Clin Oncol. 2012;30:e151–e153.
  • Cicardi M, Zingale LC, Pappalardo E, et al. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore). 2003;82:274–281.
  • Foti R, Fazio P, Lizzio G, et al. [Angioedema: first manifestation of non-Hodgkin’s lymphoma]. Ann Ital Med Int. 2002;17:185–188.
  • Mandle R, Baron C, Roux E, et al. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J Immunol. 1994;152:4680–4685.
  • Jackson J, Sim RB, Whelan A, et al. An IgG autoantibody which inactivates C1-inhibitor. Nature. 1986;323:722–724.
  • Zingale LC, Castelli R, Zanichelli A, et al. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am. 2006;26:669–690.
  • Gebhart J, Lechner K, Skrabs C, et al. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. Thromb Res. 2014;134:980–984.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.